Emerging Role of Liposomal Drug Carrier Systems in Cancer Chemotherapy
- 1 January 2003
- journal article
- review article
- Published by Taylor & Francis in Journal of Liposome Research
- Vol. 13 (1) , 17-20
- https://doi.org/10.1081/lpr-120017484
Abstract
(2003). Emerging Role of Liposomal Drug Carrier Systems in Cancer Chemotherapy. Journal of Liposome Research: Vol. 13, No. 1, pp. 17-20. doi: 10.1081/LPR-120017484Keywords
This publication has 15 references indexed in Scilit:
- Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic ToxicityJournal of Clinical Oncology, 2002
- Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinomaCancer, 2001
- A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatinBritish Journal of Cancer, 2001
- Phase I–II study of pegylated liposomal cisplatin (SPI-077™) in patients with inoperable head and neck cancerAnnals of Oncology, 2001
- Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of ChemotherapyCancer Investigation, 2001
- Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non–Small-Cell Lung Cancer and Head and Neck CancerJournal of Clinical Oncology, 1999
- Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor modelsAnti-Cancer Drugs, 1999
- Polyethylenglykol-umhülltes (pegyliertes) liposomales DoxorubicinDrugs, 1997
- Engineering liposomes for drug delivery: progress and problemsTrends in Biotechnology, 1995
- Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.Proceedings of the National Academy of Sciences, 1991